CD26 as a target against fibrous formation in chronic airway rejection lesions

Chronic lung allograft dysfunction (CLAD) after lung transplantation (Tx) is the clinical result of chronic airway rejection lesions (CARL), histomorphologically described as either obliterative remodeling of small airways or alveolar fibroelastosis, or as a combination of both. We here investigated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Life sciences (1973) 2021-08, Vol.278, p.119496-119496, Article 119496
Hauptverfasser: Jungraithmayr, Wolfgang, Yamada, Yoshito, Haberecker, Martina, Breuer, Eva, Schuurmans, Macé, Dubs, Linus, Itani, Saria, Janker, Florian, Weder, Walter, Opitz, Isabelle, Jang, Jae-Hwi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chronic lung allograft dysfunction (CLAD) after lung transplantation (Tx) is the clinical result of chronic airway rejection lesions (CARL), histomorphologically described as either obliterative remodeling of small airways or alveolar fibroelastosis, or as a combination of both. We here investigated the CD26-inhibitory effect on CD26-expressing CARL. CARL were induced by BALB/c → C57BL/6 mouse Tx under mild immunosuppression. CARL-related pro-fibrotic mediators were determined by RT-qPCR and western blotting (WB), EMT and ERK markers by WB. CD26 co-expression by immunofluorescence. CD26 was inhibited by Vildagliptin, gene depleted by CD26−/− mice. Primary lung fibroblasts were employed for ex vivo analyses. Samples from lung transplant patients with CLAD were analyzed by immunohistochemistry. CARL revealed a significantly higher expression of profibrotic proteins vs. normal lungs (p 
ISSN:0024-3205
1879-0631
DOI:10.1016/j.lfs.2021.119496